Juno Therapeutics (JUNO) Sinks 40% as Trading Resumes after Clinical Hold

November 23, 2016 8:33 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Juno Therapeutics (NASDAQ: JUNO) resumed trading down 40% after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the “ROCKET” trial. The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

FDA, Trader Talk, Trading Halts

Add Your Comment